What was Amgen's revenue and net income performance for the second quarter of 2023?

For the second quarter ended June 30, 2023, Amgen reported total revenues of $6.99 billion, an increase of 6% compared to the same period in 2022. Product sales also increased by 6% to $6.68 billion. Net income for the quarter was $1.38 billion, a 5% increase year-over-year, resulting in diluted earnings per share (EPS) of $2.57, up 5% from $2.45 in the prior year.

What is the status of the proposed acquisition of Horizon Therapeutics?

Amgen announced the proposed acquisition of Horizon Therapeutics in December 2022. However, the Federal Trade Commission (FTC) filed a lawsuit in May 2023 seeking to enjoin the acquisition, citing antitrust concerns. A preliminary injunction hearing is scheduled for September 2023. As of the filing date, the transaction's completion is uncertain and contingent on regulatory approval.

How has Amgen's debt structure changed, and what is the impact of the Horizon acquisition financing?

Amgen significantly increased its long-term debt during the first half of 2023, primarily to finance the proposed Horizon acquisition. In March 2023, the company issued $24 billion in various series of notes. As a result, total long-term debt rose from $37.4 billion at the end of 2022 to $59.4 billion by June 30, 2023. This increase in debt is a key factor in the company's financial strategy related to the acquisition.

Which products are driving Amgen's revenue growth?

Key products driving revenue growth include Prolia, which saw an 11% increase in sales for the quarter, and Repatha, with a 30% increase in sales for the quarter. EVENITY also demonstrated strong growth with a 47% increase in quarterly sales. These products, along with others, contributed to the overall increase in product sales.

AMGN 10-Q Quarterly Report Q2 FY2023 — Revenue, Net Income, EPS

Summary

Amgen Inc. reported solid financial results for the second quarter and first half of 2023, demonstrating revenue growth driven by key products like Prolia and Repatha. Total revenues for the quarter rose 6% to $6.99 billion, with product sales increasing by 6% to $6.68 billion. For the first six months, total revenues grew 2% to $13.09 billion, and product sales were up 4% to $12.53 billion. Net income for the quarter was $1.38 billion, a 5% increase year-over-year, translating to diluted EPS of $2.57, up 5%. The first half of the year saw a substantial 51% increase in net income to $4.22 billion, with diluted EPS soaring 53% to $7.86. This strong performance was bolstered by a significant increase in cash from operations and strategic debt issuances related to the proposed acquisition of Horizon Therapeutics, alongside a notable increase in long-term debt. The company continues to navigate potential regulatory challenges, particularly the FTC's lawsuit seeking to block the Horizon acquisition, with a preliminary injunction hearing scheduled. Amgen also remains engaged in ongoing patent litigation and tax disputes, though the company expresses confidence in its legal positions and financial resilience.

Financial Highlights

55 data points

Beta

Revenue

$6.99B

0.7% Gross Margin

Net Income

$1.38B

0.2% Net Margin

EPS (Diluted)

$2.57

Total Assets

$90.27B

Cash & Equivalents

$34.25B

Free Cash Flow

$3.84B

Financial Statements

Beta

Revenue	$6.99B
Cost of Revenue	$1.81B
Gross Profit	$5.17B
SG&A Expenses	$1.29B
Operating Expenses	$4.30B
Operating Income	$2.68B
Interest Expense	$752.00M
Net Income	$1.38B
EPS (Basic)	$2.58
EPS (Diluted)	$2.57
Shares Outstanding (Basic)	535.00M
Shares Outstanding (Diluted)	537.00M

Key Highlights

1Total revenues for Q2 2023 increased 6% to $6.99 billion, driven by a 6% rise in product sales to $6.68 billion.
2Diluted EPS for Q2 2023 grew 5% to $2.57, and for the first six months of 2023, it increased 53% to $7.86.
3Net income for the first six months of 2023 surged 51% to $4.22 billion, indicating strong profitability.
4Cash and cash equivalents, along with marketable securities, stood at $34.2 billion as of June 30, 2023, with $27.8 billion earmarked for the Horizon acquisition.
5Amgen issued $24 billion in new debt in Q1 2023 to finance the proposed acquisition of Horizon Therapeutics.
6The FTC is challenging the proposed acquisition of Horizon Therapeutics, with a preliminary injunction hearing set for September 2023.
7Product sales growth was led by Prolia (up 11% for the quarter) and Repatha (up 30% for the quarter).

AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2023

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions